Mammoth Biosciences disclosed non‑human primate data from its lead program showing durable triglyceride lowering after a single in‑vivo gene editing intervention, and announced plans to move the program toward a first‑in‑human trial. The program aims for a one‑time therapy to permanently reduce triglyceride levels by editing a target gene in the liver; company founders include Nobel laureate Jennifer Doudna. The primate readout provides translational proof‑of‑concept on efficacy and initial safety in a large‑animal model—key prerequisites for IND‑enabling packages. Mammoth’s announcement signals momentum in therapeutic gene editing beyond rare monogenic disorders and into metabolic indications with large patient populations. Regulators and investors will scrutinize safety data, off‑target profiles, and delivery technology (likely LNP or similar) as the program advances. If successful, an in‑vivo, durable triglyceride‑lowering therapy could reshape preventive cardiometabolic medicine by offering a single‑administration alternative to chronic pharmacotherapy.